注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Soleno Therapeutics Inc是一家临床阶段的生物制药公司。该公司专注于罕见疾病治疗药物的开发和商业化。其先导药物二氮嗪胆碱控释片(DCCR)是一种有效的ATP敏感性钾(KATP)通道激活剂。二氮嗪胆碱控释片的作用模式以大脑、胰腺和脂肪组织为靶点,有可能广泛影响Prader-Willi综合征(PWS)等复杂疾病,以减少食欲、减少食物寻求、改善饱腹感、改善胰岛素和瘦素抵抗以及减少体脂。似乎Prader-Willi综合征等情况下的许多问题行为可能有贪食驱动力作为根本原因,因此可以通过解决贪食来改善。该公司在Prader-Willi综合征中有二氮嗪胆碱控释片快速通道标志,在美国和欧盟有该药物的孤儿药标志。其开发管道包括拟议的儿童哮喘诊断设备。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
William G. Harris | 63 | 2014 | Independent Director |
Anish Bhatnagar | 51 | 2014 | President, CEO, COO & Director |
Andrew Sinclair | 49 | 2018 | Independent Director |
Ernest Mario | 82 | 2007 | Independent Chairman |
Thomas B. Casale | - | - | Member of Advisory Board |
Vinod K. Bhutani | - | - | Member of Advisory Board |
David K. Stevenson | - | - | Member of Advisory Board |
Glenis Kathleen Scadding | - | - | Member of Advisory Board |
Birgitte Volck | 62 | 2019 | Independent Director |
Gwen A. Melincoff | 72 | 2019 | Independent Director |
Robert D. Christensen | - | - | Member of Advisory Board |
Shamim Ruff | 64 | 2024 | Chair of the Development Advisory Board |
James Arthur Geraghty | 70 | 2024 | Member of Advisory Board |
Matthew Pauls | 53 | 2023 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核